Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.
<h4>Objectives</h4>To characterize the pattern of approved anti-vascular endothelial growth factor (VEGF) treatments among patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in the United Arab Emirates (UAE).<h4>Method</h4>This...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0254569 |
id |
doaj-be06a0729b344916bc03982808590ce6 |
---|---|
record_format |
Article |
spelling |
doaj-be06a0729b344916bc03982808590ce62021-07-23T04:30:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01167e025456910.1371/journal.pone.0254569Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.Igor KozakAvinash GurbaxaniAmmar SafarPrasan RaoAmal MasalmehHazar AssafMohamed FarghalyPrathamesh PathakAshok NatarajanInsaf Saffar<h4>Objectives</h4>To characterize the pattern of approved anti-vascular endothelial growth factor (VEGF) treatments among patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in the United Arab Emirates (UAE).<h4>Method</h4>This was a retrospective, nonrandomized, observational cohort analysis of the Dubai Real-world Claims Database with a 360-day follow-up period. Adult patients diagnosed with nAMD or DME treated with ranibizumab or aflibercept for the first time were included. The primary objective was to evaluate anti-VEGF treatment patterns with respect to the proportion of patients receiving ranibizumab and aflibercept for nAMD and DME separately.<h4>Results</h4>Of the 451 patients included in the final study cohort, 83.6% and 16.4% had a diagnosis of DME (ranibizumab: 48.5%; aflibercept: 51.5%) and nAMD (ranibizumab: 40.5%; aflibercept: 59.5%), respectively, at baseline. Treatment frequency of ranibizumab/aflibercept was similar for nAMD (mean: 2.4/2.9 injections; p = 0.2389) with fewer injections in the ranibizumab cohort for DME (mean: 1.9/2.5 injections; p = 0.0002). Most patients received ≤3 anti-VEGF injections during the 360-day follow-up period. The time between consecutive treatments was large (nAMD: 73.6 days/10.5 weeks; DME: 80.5 days/11.5 weeks). Approximately 10%-13.5% of patients switched their anti-VEGF therapy. Most patients (83.8%) had a diabetes diagnosis during the follow-up period.<h4>Conclusions</h4>This real-world study provides an initial understanding of anti-VEGF treatment patterns in patients with nAMD and DME in the UAE. Treatment frequency of the 2 anti-VEGF agents assessed was similar in both patient populations. Both treatments were infrequently administered with large dosing intervals.https://doi.org/10.1371/journal.pone.0254569 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Igor Kozak Avinash Gurbaxani Ammar Safar Prasan Rao Amal Masalmeh Hazar Assaf Mohamed Farghaly Prathamesh Pathak Ashok Natarajan Insaf Saffar |
spellingShingle |
Igor Kozak Avinash Gurbaxani Ammar Safar Prasan Rao Amal Masalmeh Hazar Assaf Mohamed Farghaly Prathamesh Pathak Ashok Natarajan Insaf Saffar Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai. PLoS ONE |
author_facet |
Igor Kozak Avinash Gurbaxani Ammar Safar Prasan Rao Amal Masalmeh Hazar Assaf Mohamed Farghaly Prathamesh Pathak Ashok Natarajan Insaf Saffar |
author_sort |
Igor Kozak |
title |
Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai. |
title_short |
Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai. |
title_full |
Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai. |
title_fullStr |
Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai. |
title_full_unstemmed |
Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai. |
title_sort |
treatment patterns in patients with age-related macular degeneration and diabetic macular edema: a real-world claims analysis in dubai. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2021-01-01 |
description |
<h4>Objectives</h4>To characterize the pattern of approved anti-vascular endothelial growth factor (VEGF) treatments among patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in the United Arab Emirates (UAE).<h4>Method</h4>This was a retrospective, nonrandomized, observational cohort analysis of the Dubai Real-world Claims Database with a 360-day follow-up period. Adult patients diagnosed with nAMD or DME treated with ranibizumab or aflibercept for the first time were included. The primary objective was to evaluate anti-VEGF treatment patterns with respect to the proportion of patients receiving ranibizumab and aflibercept for nAMD and DME separately.<h4>Results</h4>Of the 451 patients included in the final study cohort, 83.6% and 16.4% had a diagnosis of DME (ranibizumab: 48.5%; aflibercept: 51.5%) and nAMD (ranibizumab: 40.5%; aflibercept: 59.5%), respectively, at baseline. Treatment frequency of ranibizumab/aflibercept was similar for nAMD (mean: 2.4/2.9 injections; p = 0.2389) with fewer injections in the ranibizumab cohort for DME (mean: 1.9/2.5 injections; p = 0.0002). Most patients received ≤3 anti-VEGF injections during the 360-day follow-up period. The time between consecutive treatments was large (nAMD: 73.6 days/10.5 weeks; DME: 80.5 days/11.5 weeks). Approximately 10%-13.5% of patients switched their anti-VEGF therapy. Most patients (83.8%) had a diabetes diagnosis during the follow-up period.<h4>Conclusions</h4>This real-world study provides an initial understanding of anti-VEGF treatment patterns in patients with nAMD and DME in the UAE. Treatment frequency of the 2 anti-VEGF agents assessed was similar in both patient populations. Both treatments were infrequently administered with large dosing intervals. |
url |
https://doi.org/10.1371/journal.pone.0254569 |
work_keys_str_mv |
AT igorkozak treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT avinashgurbaxani treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT ammarsafar treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT prasanrao treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT amalmasalmeh treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT hazarassaf treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT mohamedfarghaly treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT prathameshpathak treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT ashoknatarajan treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT insafsaffar treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai |
_version_ |
1721290899509477376 |